scPharmaceuticals SCPH 深 滬
已收盤 10-03 16:00:00 美东时间
5.67
+0.010
+0.18%
華盛通- 最 高5.69
- 今 開5.67
- 成交量 381.12万股
- 最 低 5.66
- 昨 收 5.66
- 總市值 2.99亿
- 52周最高 6.2799
- 市盈率 靜 --
- 換手率 7.22%
- 52周最低 1.94
- 委 比 91.27%
- 總股本 5279.20万
- 歷史最高 18.17
- 量 比 1.68
- 振 幅 0.53%
- 歷史最低 1.94
- 每 手 1
- 風險率 0.96%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多scPharmaceuticals Issues Promissory Note to MannKind
The latest update is out from scPharmaceuticals ( ($SCPH) ). On September 23, 2...
09-25 16:25
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BRY, SCPH, WKHS on Behalf of Shareholders
NEW YORK, Sept. 22, 2025 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/o...
09-22 20:46
华兴资本医疗与生命科技行业周报【Vol.382】
来源：华兴资本 “华兴资本医疗与生命科技行业周报”定期发布，专注从资本角度解读一周数据，并提供最新行业观察。 医疗与生命科技是华兴资本多年来关注并深耕的领域，目...
09-01 08:30
美股大行评级 | 潜在涨幅163.16%！HIVE Digital Technologies获Roth Capital升目标价至7.5美元，维持"买入"评级
今日重点评级关注：Roth Capital：维持HIVE Digital Technologies"买入"评级，目标价从6美元升至7.5美元；Craig-Hallum：维持Ranpak Hldgs"买入"评级，目标价从8美元升至10美元
08-27 08:32
Craig-Hallum Downgrades scPharmaceuticals to Hold, Announces $6 Price Target
Craig-Hallum analyst Chase Knickerbocker downgrades scPharmaceuticals (NASDAQ:SCPH) from Buy to Hold and announces $6 price target.
08-27 02:01
Maxim Group Downgrades scPharmaceuticals to Hold
Maxim Group analyst Naz Rahman downgrades scPharmaceuticals (NASDAQ:SCPH) from Buy to Hold.
08-26 02:57
MannKind, Backed By Blackstone, Expands Cardiorenal Focus With $360 Million Deal
MannKind will acquire scPharmaceuticals in a $360 million deal, adding Furoscix and expanding into cardiometabolic care with a $10 billion U.S. market opportunity.
08-26 01:57
scPharmaceuticals Announces Merger with MannKind Corporation
The latest announcement is out from scPharmaceuticals ( ($SCPH) ). On August 24...
08-25 19:59
MannKind Announces Acquisition of scPharmaceuticals
An announcement from MannKind ( ($MNKD) ) is now available. On August 24, 2025,...
08-25 19:58
MannKind to Acquire scPharmaceuticals, Accelerating Revenue Growth and Emerging as a Patient-Centric Leader in Cardiometabolic and Lung Diseases
MannKind to acquire scPharmaceuticals for up to $6.35 per share, diversifying its revenue and expanding into cardiorenal medicine with FUROSCIX, a treatment for edema. The deal includes a $5.35 upfront cash payment and a contingent value right (CVR) potentially adding $1.00 per share. The upfront payment represents a 36% premium to scPharmaceuticals’ VWAP, and the total consideration a 31% premium to its August 22 closing price.FUROSCIX, which ad...
08-25 11:30
